Shire Receives Orphan Drug Designation For Gene Therapy Candidate SHP654 (BAX 888) For The Treatment Of … – Clinical Leader
|
Shire Receives Orphan Drug Designation For Gene Therapy Candidate SHP654 (BAX 888) For The Treatment Of …
Clinical Leader Shire plc, the global biotechnology leader in rare diseases, recently announced the U.S. Food and Drug Administration (FDA) awarded Orphan Drug Designation to Shire’s gene therapy candidate SHP654 (also designated as BAX 888), an investigational … |